Percutaneous peripheral nerve stimulation for the treatment of chronic neuropathic postamputation pain: a multicenter, randomized, placebo-controlled trial

被引:83
|
作者
Gilmore, Christopher [1 ]
Ilfeld, Brian [2 ]
Rosenow, Joshua [3 ]
Li, Sean [4 ]
Desai, Mehul [5 ]
Hunter, Corey [6 ]
Rauck, Richard [1 ]
Kapural, Leonardo [1 ]
Nader, Antoun [7 ]
Mak, John [4 ]
Cohen, Steven [8 ]
Crosby, Nathan [9 ]
Boggs, Joseph [9 ]
机构
[1] Clin Res Ctr, Winston Salem, NC 27103 USA
[2] Univ Calif San Diego, Anesthesiol, San Diego, CA 92103 USA
[3] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA
[4] Premier Pain Centers, Shrewsbury, NJ USA
[5] Int Spine Pain & Performance Ctr, Washington, DE USA
[6] Ainsworth Inst Pain Management, New York, NY USA
[7] Northwestern Univ, Dept Anesthesiol, Chicago, IL 60611 USA
[8] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA
[9] SPR Therapeut, Cleveland, OH USA
关键词
PHANTOM LIMB PAIN; ELECTRICAL-STIMULATION; NEUROSTIMULATION; MECHANISMS; AMPUTATION; SYSTEM;
D O I
10.1136/rapm-2018-100109
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background and objectives Chronic neuropathic pain is a common challenging condition following amputation. Recent research demonstrated the feasibility of percutaneously implanting fine-wire coiled peripheral nerve stimulation (PNS) leads in proximity to the sciatic and femoral nerves for postamputation pain. A multicenter, double-blinded, randomized, placebo-controlled study collected data on the safety and effectiveness of percutaneous PNS for chronic neuropathic pain following amputation. Methods Twenty-eight lower extremity amputees with postamputation pain were enrolled. Subjects underwent ultrasound-guided implantation of percutaneous PNS leads and were randomized to receive PNS or placebo for 4 weeks. The placebo group then crossed over and all subjects received PNS for four additional weeks. The primary efficacy endpoint evaluated the proportion of subjects reporting >= 50% pain reduction during weeks 1-4. Results A significantly greater proportion of subjects receiving PNS (n=7/12, 58%, p=0.037) demonstrated >= 50% reductions in average postamputation pain during weeks 1-4 compared with subjects receiving placebo (n=2/14, 14%). Two subjects were excluded from efficacy analysis due to eligibility changes. Significantly greater proportions of PNS subjects also reported >= 50% reductions in pain (n=8/12, 67%, p=0.014) and pain interference (n=8/10, 80%, p=0.003) after 8 weeks of therapy compared with subjects receiving placebo (pain: n=2/14, 14%; pain interference: n=2/13, 15%). Prospective follow-up is ongoing; four of five PNS subjects who have completed 12-month follow-up to date reported >= 50% pain relief. Conclusions This work demonstrates that percutaneous PNS therapy may provide enduring clinically significant pain relief and improve disability in patients with chronic neuropathic postamputation pain.
引用
收藏
页码:637 / 645
页数:9
相关论文
共 50 条
  • [31] Peripheral nerve stimulation in treatment of neuropathic trigeminal pain
    Slavin, K
    CEPHALALGIA, 2003, 23 (07) : 724 - 724
  • [32] Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials
    Dykukha, Igor
    Malessa, Rolf
    Essner, Ute
    Ueberall, Michael A.
    PAIN MEDICINE, 2021, 22 (04) : 861 - 874
  • [33] The effect of lacosamide in peripheral neuropathic pain: A randomized, double-blind, placebo-controlled, phenotype-stratified trial
    Carmland, Malin Erika
    Kreutzfeldt, Melissa Dall
    Holbech, Jakob Vormstrup
    Brask-Thomsen, Peter Kolind
    Kroigard, Thomas
    Hansen, Peter Norregaard
    Tankisi, Hatice
    Jensen, Troels Staehelin
    Bach, Flemming Winther
    Sindrup, Soren Hein
    Finnerup, Nanna Brix
    EUROPEAN JOURNAL OF PAIN, 2023, : 105 - 119
  • [34] Effects of valdecoxib in the treatment of chronic low back pain: Results of a randomized, placebo-controlled trial
    Coats, TL
    Borenstein, DG
    Nangia, NK
    Brown, MT
    CLINICAL THERAPEUTICS, 2004, 26 (08) : 1249 - 1260
  • [35] Efficacy of different spinal cord stimulation paradigms for the treatment of chronic neuropathic pain (PARS-trial): study protocol for a double-blinded, randomized, and placebo-controlled crossover trial
    Rezvan Ahmadi
    Benito Campos
    Mohammad Mehdi Hajiabadi
    Colette Doerr-Harim
    Solveig Tenckhoff
    Dirk Rasche
    Andreas Unterberg
    Jan Vesper
    Tom Bruckner
    Volker Tronnier
    Trials, 22
  • [36] Efficacy of different spinal cord stimulation paradigms for the treatment of chronic neuropathic pain (PARS-trial): study protocol for a double-blinded, randomized, and placebo-controlled crossover trial
    Ahmadi, Rezvan
    Campos, Benito
    Hajiabadi, Mohammad Mehdi
    Doerr-Harim, Colette
    Tenckhoff, Solveig
    Rasche, Dirk
    Unterberg, Andreas
    Vesper, Jan
    Bruckner, Tom
    Tronnier, Volker
    TRIALS, 2021, 22 (01)
  • [37] Predicting Outcome in Peripheral Nerve Stimulation for Chronic Neuropathic Pain
    Slotty, Philipp J.
    Vesper, Jan
    Pohlmeier, Kira
    Wille, Christian
    NEUROMODULATION, 2013, 16 (05): : 483 - 488
  • [38] TREATMENT OF PAIN WITH PANCREATIC EXTRACTS IN CHRONIC-PANCREATITIS - RESULTS OF A PROSPECTIVE PLACEBO-CONTROLLED MULTICENTER TRIAL
    MOSSNER, J
    SECKNUS, R
    MEYER, J
    NIEDERAU, C
    ADLER, G
    DIGESTION, 1992, 53 (1-2) : 54 - 66
  • [39] Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial
    Hansen, Julie Schjodtz
    Gustavsen, Stefan
    Roshanisefat, Homayoun
    Kant, Matthias
    Biering-Sorensen, Fin
    Andersen, Claus
    Olsson, Anna
    Chow, Helene Hojsgaard
    Asgari, Nasrin
    Hansen, Julie Richter
    Nielsen, Helle Hvilsted
    Hansen, Rikke Middelhede
    Petersen, Thor
    Oturai, Annette Bang
    Sellebjerg, Finn
    Saedder, Eva Aggerholm
    Kasch, Helge
    Rasmussen, Peter Vestergaard
    Finnerup, Nanna Brix
    Svendsen, Kristina Bacher
    PHARMACEUTICALS, 2023, 16 (08)
  • [40] Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
    Yosipovitch, Gil
    Stander, Sonja
    Kerby, Matthew B.
    Larrick, James W.
    Perlman, Andrew J.
    Schnipper, Edward F.
    Zhang, Xiaoming
    Tang, Jean Y.
    Luger, Thomas
    Steinhoff, Martin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) : 882 - +